Tenax Therapeutics, Inc. TENX
Set alert
1.80 USD +0.01 +0.56%
At close · Nov 2
1.79 -0.01 -0.56%
After hours · Nov 2, 4:54 PM ET
1.77 Day range 1.84
1.31 52-week range 19.40
- YTD
- -85.23%
- 1 year
- -75.48%
- Open
- 1.83
- Prev close
- 1.79
- Mkt cap
- 67.36M
- Vol
- 1.16M
- Avg vol
- 5.67M
- EPS
- -1.48
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.77
- High
- 1.84
- Forward P/E
- -1.06
- Beta
- 2.15
- Short ratio
- 1.46
- Inst. own
- 47.95%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Apr 1, 2024
- 50-d avg
- 4.96
- 200-d avg
- 3.94
- 1y target
- 16.30
3M chart
Signals (9)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Oct 30, 2026 | 3 days ago |
| SMA: Bullish | Oct 28, 2026 | 5 days ago |
| SMA: Bullish | Oct 28, 2026 | 5 days ago |
| RSI: Oversold | Oct 13, 2026 | 2 weeks ago |
| SMA: Bullish | Oct 1, 2026 | 1 month ago |
| SMA: Bullish | Sep 21, 2026 | 1 month ago |
| MACD: Buy Signal | Aug 27, 2026 | 2 months ago |
| RSI: Oversold | Aug 10, 2026 | 2 months ago |
| SMA: Bearish | Aug 5, 2026 | 2 months ago |
Key statistics
- Market cap
- 18.71M
- Enterprise value
- 7.73M
- Trailing P/E
- 0.00
- Forward P/E
- -1.06
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.20
- EPS (TTM)
- -13.05
- Beta
- 2.15
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -7.55M
- Total cash
- 9.38M
- Total debt
- 278.80K
- Return on equity
- -113.79%
- Shares outstanding
- 3.41M
- Short % of float
- 4.10%
- 50-day average
- 4.96
- 200-day average
- 3.94
Analyst view
Consensus: none
Price target (mean) 16.30 +805.6% upside
Now 1.80
- Target (low)
- 7.00
- Target (mean)
- 16.30
- Target (high)
- 30.00
Ratings (0m) 4 4 buy · 0 hold · 0 sell
- Strong buy1
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Apr 1, 2024
Expected Apr 1, 2024. Consensus EPS estimate -0.4225.
Financials — quick view
TENX Revenue — quarterly 0
TENX Net income — quarterly -17.80M
TENX EPS — quarterly -0.35
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | -1.38 | -0.19 | +1.19 | +86.23% |
| Aug 13, 2024 | Jun 1, 2024 | -1.99 | -1.83 | +0.16 | +8.04% |
| May 14, 2024 | Mar 1, 2024 | -2.40 | -3.12 | -0.72 | -30.00% |
| Apr 1, 2024 | Dec 1, 2023 | -8.15 | — | — | — |
| Nov 13, 2023 | Sep 1, 2023 | -7.20 | -6.40 | +0.80 | +11.11% |
| Aug 14, 2023 | Jun 1, 2023 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 24, 2024 | Leerink Partners | init | — | Outperform |
| Feb 20, 2024 | Roth MKM | reit | Buy | Buy |
About Tenax Therapeutics, Inc.
Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- tenaxthera.com
News
- TENX INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Tenax Therapeutics (TENX) Investors of Securities Class Action Lawsuit Deadline on December 28, 2026
- Kaplan Fox Reminds Tenax Therapeutics, Inc. (TENX) Investors with Significant Losses to Seek a Leadership Role Before Deadline on December 28, 2026
- TENX Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Tenax Therapeutics Securities Lawsuit - Contact Levi & Korsinsky
- ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Tenax Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - TENX
- TENX INVESTOR ALERT: Tenax Therapeutics, Inc. Investors with Substantial Losses May Seek to Lead Class Action Lawsuit Before December 28, 2026 Deadline
- TENX INVESTOR ALERT: Tenax Therapeutics, Inc. Investors with Substantial Losses May Seek to Lead Class Action Lawsuit Before December 28, 2026 Deadline
- SHAREHOLDER ALERT: Bronstein Gewirtz & Grossman, LLC Announces Class Action Against Tenax Therapeutics, Inc. (NASDAQ: TENX) — Investors Who Suffered Losses Are Encouraged to Contact the Firm
- ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Tenax Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - TENX
- ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Tenax Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - TENX
- TENX UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Tenax Therapeutics (TENX) Investors of Securities Class Action Lawsuit Deadline on December 28, 2026
Your note
Sign in to keep a note on TENX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DAVIDSON MICHAEL H | Director | Purchase | Aug 7, 2024 | 2,881 |
| PROEHL GERALD T | Director | Purchase | Aug 7, 2024 | 1,667 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| BVF Inc. | 9.96% | 339,549 | 1.86M | Sep 29, 2024 |
| Vivo Capital, LLC | 6.11% | 208,333 | 1.14M | Sep 29, 2024 |
| VR Adviser, LLC | 6.11% | 208,333 | 1.14M | Sep 29, 2024 |
| Velan Capital Investment Management LP | 2.44% | 83,333 | 457.50K | Sep 29, 2024 |
| Adage Capital Partners GP L.L.C. | 2.44% | 83,333 | 457.50K | Sep 29, 2024 |
| Vestal Point Capital, LP | 2.44% | 83,333 | 457.50K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Price (T.Rowe) Health Sciences Fund | 0.78% | 26,472 | 145.33K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.30% | 10,217 | 56.09K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.18% | 5,984 | 32.85K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.14% | 4,708 | 25.85K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.07% | 2,326 | 12.77K | Sep 29, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.01% | 364 | 2.00K | Oct 30, 2024 |